Scientific Teams

Previous page

Team “Genetics and development of nervous system tumors”

Presentation

Brain tumors
Main domain : Cellular & molecular neurosciences
Subdomain :  Clinical & translational neurosciences

Marc SANSON & Emmanuelle HUILLARD’s team proposes to identify new mutations and biomarkers, and understand the development of brain tumors with four major aims:
  • To improve diagnosis and treatment by expanding their molecular database and feed new translational projects
  • To characterize the function of newly identified mutations in gliomas by using the “mutation to function” pipeline successfully implemented by the team.
  • To characterize the cell intrinsic and environmental mechanisms governing brain tumor initiation and progression.
  • To develop new mouse and patient-derived models to identify actionable targets and new treatments.

Major publications

Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Sharif A, Mokhtari K, Pagnotta SM, Iavarone A, Lasorella A, Huillard E, Sanson M. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Nat Commun. 2018 Jun 18;9(1):2371 (IF=12.1)

Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathol. 2018 May;135(5):743-755. (IF=12.2)

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M,Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 1;22(5):1185-96. (IF=9.6)

Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, Pastinen T, Hallout S, Figarella-Branger D, Dehais C, Idbaih A, Mokhtari K, Delattre JY**, Huillard E**, Mark Lathrop G**, SansonM**, Houlston RS**; POLA Network. TCF12 is mutated in anaplastic oligodendroglioma. Nat Commun. 2015 Jun 12;6:7207. (IF=12.1).

Gleize V, Alentorn A, Connen de Kérillis L, Labussière M, Nadaradjane AA, Mundwiller E, Ottolenghi C, Mangesius S, Rahimian A, Ducray F; POLA network., Mokhtari K, Villa C, Sanson M. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol. 2015 Sep;78(3):355-74. (IF=9.9)

More information Hide

Team members

  • Ahmed IDBAIH

    Principal Investigator, MD, PhD, MCU-PH, Sorbonne University, AP-HP

    More information
  • Franck BIELLE

    Principal Investigator, MD, PhD, MCU-PH, Sorbonne University, AP-HP

    More information
  • Isabelle LEROUX

    Principal Investigator, PhD, CRCN, INSERM

    More information
  • Michel KALAMARIDES

    Principal Investigator, MD, PhD, PU-PH, Sorbonne University, AP-HP

    More information
  • Michel MALLAT

    Principal investigator, PhD, DR2, INSERM

    More information